Markers of Coagulation and Fibrinolysis as Measures of Disease Activity in Inflammatory Bowel Disease

References

• De Dombal FT, Softley A. IOIBD report no. 1: Observer variation in calculating indices of severity and activity in Crohn’s disease. Gut 1987;28: 474–81.
   Google Scholar
• Kjeldsen J, Schaffalitzky de Muckadell OB. Assessment of disease severity and activity in inflammatory bowel disease. Scand J Gastroenterol 1993;28:1–9.
   PubMed Web of Science ®Google Scholar
• Fagan EA, Dyck RF, Maton PN, Hodgson HJF, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest 1982;12:351–9.
   PubMed Web of Science ®Google Scholar
• Buckell NA, Lennard-Jones JE, Hernandez MA, Kohn J, Riches PG, Wadsworth J. Measurements of serum proteins during attacks of ulcerative colitis as a guide to patient management. Gut 1979;20:22–7.
   PubMedGoogle Scholar
• Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn’s disease. J Clin Gastroenterol 1988;10:401–5.
   PubMed Web of Science ®Google Scholar
• Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzáles D, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883–9.
   Google Scholar
• Chamouard P, Grunebaum L, Wiesel M-L, Frey PL, Wittersheim C, Sapin R, et al. Prothrombin fragment 1+2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995;7: 1183–8.
   Google Scholar
• Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AAM, et al. Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction. Lancet 1989;2:1057–62.
   PubMed Web of Science ®Google Scholar
• Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R, et al. Granulomatous vasculitis in Crohn’s disease. Gastroenterology 1991;100:1279–87.
   PubMed Web of Science ®Google Scholar
• Talbot RW, Heppell J, Dozois RR, Beart RWJ. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140–5.
   PubMed Web of Science ®Google Scholar
• Edwards RL, Levine JB, Green R, Duffy M, Mathews E, Brande W, et al. Activation of blood coagulation in Crohn’s disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterology 1987;92:329–37.
   Google Scholar
• Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis 1992;3:773–8.
   PubMed Web of Science ®Google Scholar
• van Wersch JW, Houben P, Rijken J. Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 1990;28:513–7.
   Google Scholar
• Van Bodegraven AA, Tuynman HARE, Schoorl M, Kruishoop AM, Bartels PCM. Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol 1995;30:580–5.
   Google Scholar
• Novacek G, Kapiotis S, Moser G, Speiser W, Gangl A, Vogelsang H. No evidence of activated blood coagulation in Crohn’s disease. Eur J Gastroenterol Hepatol 1997;9:963–7.
   PubMedGoogle Scholar
• Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease. Response to therapy. Dig Dis 1978;23:897–902.
   Google Scholar
• Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353–6.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;1:514.
   PubMed Web of Science ®Google Scholar
• Kjeldsen J, Schaffalitzky de Muckadell O, Lauritsen K. Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease. Scand J Gastroenterol 1997;32:933–41.
   PubMed Web of Science ®Google Scholar
• Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn’s disease in the county of Copenhagen, 1962 to 1978. Gastroenterology 1982;83: 563–8.
   Google Scholar
• Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn’s Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984; 86:249–66.
   PubMed Web of Science ®Google Scholar
• Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993;117:71–7.
   PubMedGoogle Scholar
• Mannucci PM, Giangrande PLF. Detection of the prethrombotic state due to procoagulant imbalance. Eur J Haematol 1992;48: 65–9.
   PubMedGoogle Scholar
• Nieuwenhuizen W. Quantitative enzyme immunoassays for degradation products of fibrinogen (FgDP), fibrin (FbDP) and total of FgDP and FbDP (TDP). In: Jespersen J, Bertina RM, Haverkate F, editors. ECAT assay procedures. A manual of laboratory techniques. Dordrecht: Kluwer; 1992. p. 191–203.
   Google Scholar
• Roberts HR, Tabares AH. Overview of the coagulation reactions. In: High KA, Roberts HR, editors. Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, Inc.; 1995. p. 35–50.
   Google Scholar
• Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Condomines J, et al. Low levels of plasminogen activator inhibitor type I in patients with inflammatory bowel disease. Fibrinolysis 1994;8: 359–63.
   Google Scholar
• Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 1990;4:25–40.
   Google Scholar
• Leroy-Matheron C, Gouault-Heilmann M. Influence of conditions of blood sampling on coagulation activation markers (prothrombin fragment 1+2, thrombin-antithrombin complexes and D-dimers) measurements. Thromb Res 1994;74:399–407.
   PubMed Web of Science ®Google Scholar
• Bauer KA, Barzegar S, Rosenberg RD. Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 +2 measurements. Thromb Res 1991;63: 617–28.
   Google Scholar
• Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995;108:1011–5.
   Google Scholar
• Gabazza EC, Osamu T, Yamakami T, Ibata H, Sato T, Sato Y, et al. Correlation between clotting and collagen metabolism markers in rheumatoid arthritis. Thromb Hemost 1994;71:199–204.
   PubMed Web of Science ®Google Scholar
• Stadnicki A, Kloczko J, Nowak A, Sierka E, Sliwinski Z. Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis. Am J Gastroenterol 1991;86:690–3.
   Google Scholar
• de Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989;30:188–94.
   Google Scholar
• Conlan MG, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989;34:1089–93.
   Google Scholar
• van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622–7.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, Eerenberg AJM, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253–9.
   PubMed Web of Science ®Google Scholar
• Salgado A, Bovéda JL, Monasterio J, Segura RM, Mourelle M, Gómez-Jimenez J, et al. Inflammatory mediators and their influence on haemostasis. Haemostasis 1994;24:132–8.
   PubMedGoogle Scholar
• Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114–20.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Levi M, ten Cate H, van Deventer SJH. The role of tumor necrosis factor in systemic inflammatory responses in primate endotoxemia. Prog Clin Biol Res 1994. p. 425–33.
   Google Scholar
• Fantuzzi G, Ghezzi P. Glucocorticoids as cytokine inhibitors: role in the neuroendocrine control and therapy of inflammatory diseases. Mediators Inflam 1993;2:263–70.
   PubMedGoogle Scholar
• van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody. Gastroenterology 1995;109:129–35.
   PubMed Web of Science ®Google Scholar